SMITH JASON DREW (General Counsel) sold 15.3% of their position (7.52K shares) of UROGEN PHARMA LTD. on the open market
Open‑market sale worth $144.0K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 7/30/2025ACC: 0001437749-25-023963
Officer· General Counsel
Since Aug 2020
+8.98K
Net shares
Net buyer
$144.0K
Total sold
1
Open market trades
0B · 1S
2
Total transactions
16.50K acquired · 7.52K disposed
Non-Derivative Transactions2
Ordinary Shares
Direct
Shares
+16.50K
Price / share
—
Trade value
—
% of position
50.7%
7/28/2025
32.51K→49.01K
Ordinary Shares
Direct
Shares
−7.52K
Price / share
$19.14
Trade value
$143.97K
% of position
15.3%
7/28/2025
49.01K→41.49K
Total
Net shares
+8.98K
Net value
-$143.97K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares Direct | 7/28/2025 | M · Option Exercise | +16.50K | — | — | 50.7% | 32.51K | 49.01K |
| Ordinary Shares Direct | 7/28/2025 | S · Sale | −7.52K | $19.14 | $143.97K | 15.3% | 49.01K | 41.49K |
| Total | +8.98K | -$143.97K | ||||||
Derivative Transactions0
No derivative transactions reported